General MedicationsINTRAVENOUSGeneric
VAPRISOL
CONIVAPTAN HYDROCHLORIDE
Standard Dose
20MG/4ML (5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview VAPRISOL is listed in Drugs@FDA under application 021697 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CONIVAPTAN HYDROCHLORIDE Form and strength INJECTABLE;INTRAVENOUS - 20MG/4ML (5MG/ML) Sponsor CUMBERLAND Submission history Latest submission status date: 2016-10-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview VAPRISOL is listed in Drugs@FDA under application 021697 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CONIVAPTAN HYDROCHLORIDE Form and strength INJECTABLE;INTRAVENOUS - 20MG/4ML (5MG/ML) Sponsor CUMBERLAND Submission history Latest submission status date: 2016-10-14 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.